Cell and Gene Therapy Bio-manufacturing Market Key Players Analysis - Getinge AB, Infors AG, Lonza Group Ltd, Merck KGaA, Miltenyi Biotec B.V. & Co. K.G., PIERRE GUERIN.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Cell and Gene Therapy Bio-manufacturing Market Size, Share & Trends Analysis Report By Product Type (Consumables, Equipment, And Software Solutions), Usage (Commercial-Stage Manufacturing And Research-Stage Manufacturing), Application (Upstream Processing, Harvesting, And Downstream Processing), And End-User (Life Science Companies, Contract Research Organizations (Cros), Contract Manufacturing Organizations (CMOs), And Cell Banks)- Market Outlook And Industry Analysis 2034"

The global cell and gene therapy bio-manufacturing market is estimated to reach over 40.2 billion by the year 2034, exhibiting a CAGR of 11.4% during the forecast period.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1692

The global cell and gene therapy biomanufacturing market is poised for significant growth, driven primarily by the increasing number of regulatory-approved therapies and the rising demand for advanced manufacturing infrastructure. The expanding range of target indications for these therapies is further intensifying the requirement for large-scale biomanufacturing capabilities.

Market growth is supported by substantial capital investments from government entities and leading industry players, with approximately USD 2.3 billion invested in gene therapy companies over the past decade, reflecting strong engagement from major pharmaceutical and biotechnology firms in advancing gene therapy technologies.

In addition, contract development and manufacturing organizations (CDMOs/CMOs), alongside internal manufacturing units, are increasingly prioritizing cell and gene therapy as a strategic growth focus. Sustained investments in research and development by pharmaceutical and biotechnology companies underscore the sector's expansion potential. According to the U.S. Food and Drug Administration (USFDA), the number of cell and gene therapy candidates entering early-stage development pipelines has risen considerably. These trends collectively indicate robust market growth prospects throughout the forecast period.

List of Prominent Players in the Cell and Gene Therapy Bio-manufacturing Market:
• Becton, Dickinson and Company
• Endress+Hauser Group Services AG (Analytik Jena GmbH)
• Danaher Corporation
• Bio-Rad Laboratories, Inc.
• Bio-Techne Corporation
• General Electric Company (G.E. Healthcare)
• Getinge AB
• Infors AG
• Lonza Group Ltd
• Merck KGaA
• Miltenyi Biotec B.V. & Co. KG
• PIERRE GUERIN
• Sartorius AG (Sartorius Stedim Biotech S.A.)
• Thermo Fisher Scientific Inc.
• WuXi AppTec

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-01

Market Dynamics
Drivers:
The expansion of the global cell and gene therapy biomanufacturing market is being significantly driven by the rising prevalence of cancer and other targeted diseases, alongside increased research and development investments by pharmaceutical companies. According to GLOBOCAN 2020 data from the International Agency for Research on Cancer (IARC), the worldwide cancer burden has reached 19.3 million cases, highlighting the urgent need for innovative therapeutic solutions such as gene therapies.

Additionally, the global prevalence of osteoporosis was reported at 18.3%, as outlined in a systematic analysis published in the Journal of Orthopedic Surgery and Research in October 2021. Stem cell-based interventions for osteoporosis demonstrate substantial potential to reduce fracture risks, and as orthopedic conditions become increasingly common, the demand for specialized cell and gene therapy manufacturing services is projected to rise, supporting sustained market growth.

Challenges:
A major challenge facing the cell and gene therapy biomanufacturing sector is the high cost of advanced therapies. The significant financial burden on patients, healthcare systems, and insurers continues to restrict widespread adoption. For example, in May 2022, the U.S. Food and Drug Administration (FDA) approved a chimeric antigen receptor (CAR) T-cell therapy for pediatric and young adult patients with refractory or relapsed B-cell precursor acute lymphoblastic leukemia, with a single-dose cost of approximately USD 475,000. Such high pricing limits accessibility, thereby constraining overall market growth.

Regional Trends:
North America is expected to maintain a leading position in the cell and gene therapy biomanufacturing market in terms of revenue and is projected to register a strong compound annual growth rate (CAGR) over the forecast period. This growth is primarily driven by the region's increasing prevalence of infectious and chronic diseases and a rapidly aging population.

Gene therapies are widely utilized in diagnostics, therapeutics, drug discovery, and oncology research, with the United States serving as a central hub due to its substantial disease burden. Consequently, demand for cell and gene therapies in North America is anticipated to remain robust, supported by an advanced healthcare infrastructure and an expanding patient population.

Recent Developments:
• In January 2022, AllogeneTherapeutics Inc and AntionBiosciences Inc. formed an exclusive collaboration and global license agreement for Antion's miRNA technology (miCAR) to advance multiplex gene silencing as an additional tool in the development of next-generation allogeneic CAR T products.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1692

Segmentation of Cell and Gene Therapy Bio-manufacturing Market-
By Product Type-
• Consumables
o Culture Supplements
 Media
 Serum
 Macronutrients
o Single-Use Liquids
o Cell Culture Reagents
o Cell Quantification Kits
• Equipment
o Bioreactors/Fermenters
 Continuous Bioreactors
 Single-Use Bioreactors
o Mixing Systems
o Cell Counters
o Cell Sorters
o Centrifuges
o Incubators
o Biosafety Cabinets
o Freezers
o PCR Systems
o Transfection Systems
o Storage Tanks
o Others
• Software Solutions
By Usage-
• Commercial Stage Manufacturing
• Research Stage Manufacturing
By Application-
• Upstream Processing
o Formulation and Hydration
o Cell Culture Processing
• Harvesting
• Downstream Processing
o Separation and Filtration
o Fill and Finish Operations
By End-User-
• Life Science Companies
o Equipment
o Consumables
o Software Solutions
• Contract Research Organizations (CROs)
o Equipment
o Consumables
o Software Solutions
• Contract Manufacturing Organizations (CMOs)
o Equipment
o Consumables
o Software Solutions
• Cell Banks
o Equipment
o Consumables
o Software Solutions
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/cell-and-gene-therapy-bio-manufacturing-market/1692

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.